Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-50 vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesia.
Mild to moderate pain,Fever
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily metabolized by CYP3A4 to norfentanyl and other inactive metabolites. Minimal metabolism via CYP3A5. Less than 1% excreted unchanged in urine.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~80–85% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein (AAG).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
3–8 L/kg (mean ~4 L/kg). High Vd indicates extensive tissue distribution (e.g., muscle, fat). Clinical meaning: large reservoir; slow redistribution contributes to long half-life.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Transdermal: ~92% relative to IV fentanyl (due to first-pass metabolism avoidance; absolute bioavailability ~45% for gel reservoir, ~40% for matrix patch). Not used orally (poor bioavailability <30%).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-59 m L/min: reduce dose by 50% and monitor closely. GFR <30 m L/min: contraindicated due to accumulation of active metabolite.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% and monitor. Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Approved for opioid-tolerant children ≥2 years; dose based on morphine equivalent daily dose (MEDD) conversion; apply system every 72 hours; initial dose not to exceed 25 mcg/h.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lowest available dose (25 mcg/h) and titrate slowly; monitor for respiratory depression, sedation, and constipation; consider reduced clearance and increased sensitivity.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: RISK OF MEDICATION ERRORS, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION IN CHILDREN.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression, especially in non-opioid-tolerant patients or with dose initiation/titration,Risk of hypotension, bradycardia, and QT prolongation,Risk of serotonin syndrome with serotonergic drugs,Risk of adrenal insufficiency with prolonged use,Risk of severe hypotension in patients with compromised ability to maintain blood pressure,Use caution in patients with head injury, increased intracranial pressure, or impaired consciousness,May obscure the course of acute abdominal conditions,Risk of withdrawal with abrupt discontinuation,Application site reactions,Fever may increase fentanyl absorption through the skin,Not indicated for acute or postoperative pain,Should be used only in opioid-tolerant patients for chronic pain
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to fentanyl or any component of the system,Opioid-non-tolerant patients (including patients with acute or postoperative pain),Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Suspected or known paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit and grapefruit juice as they may increase fentanyl levels. No other significant food interactions.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C. First trimester: No adequate human data; animal studies show increased risk of skeletal variations. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression at birth. Avoid during labor due to risk of neonatal respiratory depression.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Fentanyl is excreted in breast milk. Milk-to-plasma ratio is approximately 0.87-1.0. Use caution; monitor infant for drowsiness, feeding difficulties, and respiratory depression. American Academy of Pediatrics recommends use only if benefit outweighs risk.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy can increase fentanyl clearance due to increased plasma volume and hepatic metabolism. Gradual dose increments may be needed to maintain analgesia. However, avoid use during labor and delivery. If required, use lowest effective dose and have resuscitation equipment available.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Convert oral morphine to transdermal fentanyl using a 100:1 ratio (e.g., oral morphine 100 mg/day = fentanyl 100 mcg/hr patch). Rotate patch sites every 72 hours to avoid skin irritation; apply to non-irradiated, intact skin. Do not cut or damage the patch. Initiate only in opioid-tolerant patients. Titrate no more frequently than every 72 hours. Monitor for respiratory depression, especially in opioid-naive patients, COPD, or sleep apnea. Naloxone may be needed but duration of fentanyl action may exceed naloxone's effect. Heat exposure (e.g., fever, heating pads) increases absorption and risk of toxicity. Remove old patch before applying new one.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Apply patch to flat, non-hairy skin on chest, back, or upper arm; avoid irritated or scarred skin.,Wash hands after applying; do not touch the gel or cut the patch.,Dispose of used patches by folding adhesive sides together and flushing down toilet or placing in child-resistant container.,Avoid heating pads, hot tubs, electric blankets, or sunbathing while wearing patch.,Do not stop or change dose without talking to doctor; withdrawal may occur.,Keep patches out of reach of children and pets; accidental exposure can be fatal.,Common side effects include nausea, constipation, drowsiness, and dizziness.,Seek emergency care if you have trouble breathing, slow heartbeat, or severe drowsiness.,Do not drink alcohol or take other sedatives without doctor approval.,If patch falls off, apply a new one at a different site and note the time to track 72-hour schedule.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-50 vs ACEPHEN, answered by our medical review team.
DURAGESIC-50 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-50 and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-50 is: Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-50 and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-50 is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human data; animal studies show increased risk of skeletal variations. Second and third trimesters: Prolonged use may cause n. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.